Silver Oak Securities Incorporated Buys 288 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Silver Oak Securities Incorporated raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 84.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 631 shares of the company’s stock after purchasing an additional 288 shares during the period. Silver Oak Securities Incorporated’s holdings in IDEXX Laboratories were worth $260,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Financial Advocates Investment Management boosted its stake in IDEXX Laboratories by 28.7% during the fourth quarter. Financial Advocates Investment Management now owns 1,008 shares of the company’s stock valued at $417,000 after buying an additional 225 shares during the last quarter. Weaver Capital Management LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $261,000. Hager Investment Management Services LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at $179,000. Paragon Capital Management Inc. increased its position in IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock worth $1,579,000 after purchasing an additional 782 shares during the last quarter. Finally, Ninety One SA PTY Ltd raised its stake in IDEXX Laboratories by 8.3% during the fourth quarter. Ninety One SA PTY Ltd now owns 4,457 shares of the company’s stock valued at $1,843,000 after purchasing an additional 341 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.2 %

NASDAQ:IDXX opened at $459.78 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The stock has a fifty day simple moving average of $428.35 and a 200-day simple moving average of $453.44. The company has a market cap of $37.65 billion, a price-to-earnings ratio of 43.09, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Finally, Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $524.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.